Podcast Episodes

Back to Search
The FDA peptides vote is days away. This insider expects approval
The FDA peptides vote is days away. This insider expects approval

Episode 74

In episode 74, Jonathan Stern sits down with Dr. Jesse Morse, a board-certified family and sports medicine physician, longtime peptide prescriber who…

3 hours ago

Short Long
View Episode
Ryan MacDonald: Peptides could be a $30B+ market, and Hims is positioned to win meaningful share
Ryan MacDonald: Peptides could be a $30B+ market, and Hims is positioned to win meaningful share

Episode 73

In Hims House episode 73, Jonathan Stern talks with Needham’s Ryan MacDonald, the lead Hims & Hers analyst with a $35 price target and Buy rating. Th…

1 week, 1 day ago

Short Long
View Episode
🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims
🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims

Episode 72

In episode 72 of Hims House, Jonathan Stern interviews David Wells, Hims board member and former Netflix CFO, about his recent $1.2 million open-mark…

2 weeks ago

Short Long
View Episode
Hedge funder Ignacio Canto on retail cults, Hims as Costco + Netflix, and why Hims has 10x upside
Hedge funder Ignacio Canto on retail cults, Hims as Costco + Netflix, and why Hims has 10x upside

Episode 71

In Hims House episode 71, Jonathan Stern sits down with hedge fund manager Ignacio Canto -- founder & portfolio manager at X-Square Capital, which he…

3 weeks ago

Short Long
View Episode
Hedge fund manager Imran Khan bought more Hims at its most hated moment -- here's why
Hedge fund manager Imran Khan bought more Hims at its most hated moment -- here's why

Episode 67

In Hims House episode 70, Jonathan Stern sits down with hedge fund manager Imran Khan, founder and CIO of Proem Asset Management and a Hims sharehold…

4 weeks, 1 day ago

Short Long
View Episode
Cremieux - Half of America could be on GLP-1s by 2030 (and why peptides are probably overhyped)
Cremieux - Half of America could be on GLP-1s by 2030 (and why peptides are probably overhyped)

Episode 69

In episode 69 of Hims House, Jonathan Stern welcomes back researcher and data analyst Cremieux to take stock of the GLP-1 and peptides market. Cremie…

1 month ago

Short Long
View Episode
Sagar & Sahil Chopra - Founders of Empower Sleep on AI-powered sleep care and the Hims opportunity
Sagar & Sahil Chopra - Founders of Empower Sleep on AI-powered sleep care and the Hims opportunity

Episode 68

In episode 68, Jonathan Stern hosts Sagar and Sahil Chopra, founders of Empower Sleep, to unpack why sleep care is still fragmented, slow, and overly…

1 month, 2 weeks ago

Short Long
View Episode
Eli Dorf (Bask Health) - What is Hims’ moat if anyone can launch a telehealth startup overnight?
Eli Dorf (Bask Health) - What is Hims’ moat if anyone can launch a telehealth startup overnight?

Episode 67

In episode 67 of Hims House, Jonathan Stern hosts Eli Dorf, founder and president of Bask Health. Bask provides the operating infrastructure for tele…

1 month, 3 weeks ago

Short Long
View Episode
Brian Birnbaum - Hims & Hers Q1 earnings breakdown and the long-term bull case for Hims
Brian Birnbaum - Hims & Hers Q1 earnings breakdown and the long-term bull case for Hims

Episode 64

Thanks to our partner:

Superpower - https://superpower.com


Subscribe to Hims House:

https://himshouse.com


Brian's excellent essay on Hims:

https://thepsyc…

2 months ago

Short Long
View Episode
Mansi Hukmani - The #1 peptide Substacker on peptide culture, supply-chain race & coming gold rush
Mansi Hukmani - The #1 peptide Substacker on peptide culture, supply-chain race & coming gold rush

Episode 65

In episode 65 of Hims House, Jonathan Stern talks with Mansi Hukmani, founder of Chief Longevity Officer, about how peptide culture moved from biohac…

2 months, 2 weeks ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us